Summit Therapeutics (NASDAQ:SMMT) Share Price Breaks Above Two Hundred Day Moving Average – Time to Sell?

Shares of Summit Therapeutics PLC (NASDAQ:SMMT) passed above its 200-day moving average during trading on Friday. The stock has a 200-day moving average of $16.15 and traded as high as $16.36. Summit Therapeutics shares last traded at $16.33, with a volume of 5,783,922 shares trading hands.

Key Headlines Impacting Summit Therapeutics

Here are the key news stories impacting Summit Therapeutics this week:

• Positive Sentiment: HC Wainwright raised its 2026 and 2027 EPS forecasts, projecting narrower losses, and maintained its Buy rating. Its FY2027 loss estimate improved to $0.98 per share from $1.05, with several quarterly estimates also revised upward. MarketBeat Summit Therapeutics coverage
• Positive Sentiment: A separate healthcare-stock roundup also identifies Summit among stocks analysts are bullish on, adding to the positive analyst tone. Analysts Are Bullish on These Healthcare Stocks
• Neutral Sentiment: A technical-market report says SMMT moved above its 200-day moving average. That may be viewed as a positive momentum signal, although the article’s headline raises the possibility of selling and offers no clear new fundamental catalyst. Summit Therapeutics Stock Breaks Above 200 Day Moving Average

Wall Street Analyst Weigh In

Several research firms have recently commented on SMMT. Wall Street Zen upgraded Summit Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, September 5th. Guggenheim reiterated a “buy” rating on shares of Summit Therapeutics in a research report on Wednesday, August 26th. The Goldman Sachs Group set a $41.00 price objective on shares of Summit Therapeutics and gave the company a “buy” rating in a research note on Tuesday, September 29th. Weiss Ratings restated a “sell (d-)” rating on shares of Summit Therapeutics in a research report on Thursday, October 15th. Finally, Barclays upped their price objective on shares of Summit Therapeutics from $18.00 to $20.00 and gave the stock an “equal weight” rating in a research report on Thursday, October 1st. One research analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, seven have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Summit Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $28.61.

Summit Therapeutics Stock Up 15.1%

The stock’s fifty day simple moving average is $16.25 and its 200-day simple moving average is $16.15. The company has a market capitalization of $13.06 billion, a PE ratio of -15.26 and a beta of -1.49.

Hedge Funds Weigh In On Summit Therapeutics

Several hedge funds have recently bought and sold shares of SMMT. IFP Advisors Inc boosted its position in Summit Therapeutics by 792.3% during the third quarter. IFP Advisors Inc now owns 1,508 shares of the company’s stock worth $26,000 after purchasing an additional 1,339 shares in the last quarter. Ball & Co Wealth Management Inc. acquired a new stake in Summit Therapeutics in the first quarter valued at $28,000. Toth Financial Advisory Corp acquired a new stake in Summit Therapeutics in the third quarter valued at $30,000. CX Institutional increased its position in shares of Summit Therapeutics by 244.8% in the third quarter. CX Institutional now owns 2,038 shares of the company’s stock valued at $34,000 after buying an additional 1,447 shares in the last quarter. Finally, Eurizon Capital SGR S.p.A. purchased a new position in shares of Summit Therapeutics in the third quarter valued at $34,000. 4.61% of the stock is owned by hedge funds and other institutional investors.

Summit Therapeutics Company Profile

Summit Therapeutics is a clinical-stage biopharmaceutical company focused on developing medicines for cancer. Its lead candidate is ivonescimab, a bispecific antibody designed to target both PD-1 and VEGF, two pathways involved in tumor growth and the immune response. The company is evaluating the treatment in clinical trials for multiple types of cancer.

Summit licensed rights to develop and commercialize ivonescimab from China-based Akeso in 2022. Summit’s licensed territory covers markets outside China, including the United States, Canada, Europe and Japan.